Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.190 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock to Target This Week and 2 We Question
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
Myriad Genetics Inc (NASDAQ:MYGN) Stock Surges 19.6% on Strong Q4 Earnings Beat ↗
Via Chartmill
News headline image
3 Healthcare Stocks with Open Questions
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Shareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may ha... 
Via StockStory
News headline image
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha... 
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
3 Stocks Under $10 We Keep Off Our Radar
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many ... 
Via StockStory
News headline image
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company announced the launch of... 
Via StockStory
Topics Earnings Economy Stocks
News headline image
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Launch Represents Significant Step to Broader Commercialization 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key... 
Via StockStory
Topics Economy Government Stocks
News headline image
Why Myriad Genetics (MYGN) Stock Is Trading Up Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst... 
Via StockStory
Topics Government World Trade
News headline image
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript ↗
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript 
Via The Motley Fool
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full... 
Via StockStory
News headline image
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Government World Trade
News headline image
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Management will participate in three upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Cash-Burning Stocks We Keep Off Our Radar
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
News headline image
1 Small-Cap Stock on Our Watchlist and 2 That Underwhelm
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Economy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.